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ABSTRACT
The main objectives of this study were to quantify the 
consumption of antimicrobials on a convenience sample 
of dairy herds and to determine the association between 
herd-level antimicrobial consumption and inhibition 
zone diameters (IZD) of non-aureus staphylococci and 
Staphylococcus aureus isolates from subclinical mastitis 
cases. Also, the association between the IZD of non-
aureus staphylococci and Staph. aureus isolates within 
a herd was studied. Antimicrobial consumption data 
on 56 Flemish dairy farms were obtained between 2013 
and 2014 by so-called garbage can audits and expressed 
as antimicrobial treatment incidence (ATI), with the 
unit of ATI being the number of defined daily doses 
animal (DDDA) used per 1,000 cow-days. The average 
total ATI in adult dairy cattle for all active substances 
was 18.73 DDDA per 1,000 cow-days and ranged from 
6.28 to 42.13 DDDA between herds. The ATI of criti-
cally important (for human health) antimicrobials was 
6.91 DDDA per 1,000 cow-days; that is, 37% of total 
antimicrobial consumption. The average ATI for intra-
mammary therapy of (sub)clinical mastitis, intramam-
mary dry-cow therapy, and systemically administered 
therapy was 5.20, 6.70, and 6.73 DDDA, respectively. 
The IZD of 239 non-aureus staphylococci and 88 Staph. 
aureus isolates originating from milk samples from cows 
with subclinical mastitis collected on selected dairy 
herds were determined using Kirby-Bauer disk diffu-
sion and ranged between 6 and 42 mm. Because only 
a limited number of clinical breakpoints (Clinical and 
Laboratory Standards Institute) and epidemiological 
cut-off values (European Committee on Antimicrobial 
Susceptibility Testing) are available for mastitis-caus-
ing bacteria in bovine, IZD were used as a proxy for 
antimicrobial resistance. Inhibition zone diameters of 
non-aureus staphylococci for cefquinome, a critically 
important β-lactam antibiotic, were negatively associ-
ated with the ATI of critically important β-lactam for 
systemically administered therapy and positively with 
the ATI for intramammary therapy of (sub)clinical 
mastitis of critically important β-lactam antimicrobials. 
Only for neomycin was a positive association between 
the IZD of non-aureus staphylococci and Staph. aureus
isolates within the same herd observed.
Key words: antimicrobial consumption, staphylococci, 
subclinical mastitis, inhibition zone diameters
INTRODUCTION
Acquired antimicrobial resistance is a growing global 
concern in both human and veterinary medicine because 
it can result in treatment failure. The 2 main factors in-
volved in the development of antimicrobial resistance in 
bacteria are the presence of resistance genes and selec-
tion pressure caused by the use of antimicrobials (Levy, 
1997; Acar and Moulin, 2006; Silbergeld et al., 2008; 
Chantziaras et al., 2014). In dairy cattle, most antimi-
crobials are being used for the prevention and control 
of mastitis (Mitchell et al., 1998; Pol and Ruegg, 2007b; 
Menéndez González et al., 2010; Stevens et al., 2016). 
Potential associations between antimicrobial consump-
tion on dairy herds and antimicrobial susceptibility of 
bovine mastitis pathogens have been studied, but not 
in Europe and not in much detail (Rajala-Schultz et al., 
2004; Pol and Ruegg, 2007a; Saini et al., 2012b).
Over the last 10 yr, non-aureus staphylococci, also 
referred to as CNS, have become the most common 
cause of subclinical mastitis worldwide (Chaffer et al., 
1999; Rajala-Schultz et al., 2004; Piepers et al., 2007; 
Vanderhaeghen et al., 2014; Sztachańska et al., 2016), 
particularly in heifers (De Vliegher et al., 2012). They 
form a heterogeneous group of more than 50 species, 
of which approximately 10 have been associated with 
IMI in dairy cattle (Vanderhaeghen et al., 2014) and 
are abundantly present in bulk milk (De Visscher et 
al., 2017). Non-aureus staphylococci are also present in 
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other bovine-associated habitats such as air, housing, 
bedding material, milking equipment, and body parts 
such as teat apices, hair coat, nares, and the vagina 
(White et al., 1989; Nagase et al., 2002; Paduch and 
Kroemker, 2011; Piepers et al., 2011; Piessens et al., 
2012; Braem et al., 2013; De Visscher et al., 2014, 
2016). Their omnipresence, especially on the body of 
the cows, implies that non-aureus staphylococci are 
generally more exposed to antimicrobial treatments 
than other mastitis pathogens, which could explain the 
higher levels of antimicrobial resistance of non-aureus 
staphylococci compared with the more pathogenic 
Staphylococcus aureus (Owens and Watts, 1988; Tapo-
nen and Pyorala, 2009; Schmidt et al., 2015). It has 
been suggested that non-aureus staphylococci might 
act as a potential reservoir for resistance genes that can 
be transferred and integrated into the genome of Staph. 
aureus (Holmes and Zadoks, 2011; Otto, 2013; Vitali et 
al., 2014).
One of the most widely used methods for measuring 
antimicrobial susceptibility of bacteria is the Kirby-
Bauer disk diffusion test, in which radial zones of bac-
terial growth inhibition are cross-referenced to break-
points to determine whether an organism is susceptible 
or resistant to therapy with a particular antimicrobial 
drug (Traub and Leonhard, 1994). Still, the required 
clinical breakpoints to correctly interpret the results are 
often unavailable for a specific combination of pathogen 
and antimicrobial per host species (CLSI, 2008, 2015; 
http:// www .eucast .org/ ast _of _veterinary _pathogens/ 
). This is the case particularly for non-aureus staphy-
lococci isolated from bovine milk, partly because they 
are generally considered minor pathogens and typically 
not treated with antimicrobials. Using inhibition zone 
diameters (IZD) for non-aureus staphylococci and for 
Staph. aureus to determine the presence of (acquired) 
genetic resistance elements as a proxy for potential an-
timicrobial resistance, rather than relying on (clinical) 
breakpoints, avoids these issues.
The main objectives of this study were (1) to quan-
tify the use of antimicrobials on a convenience sample 
of dairy herds, (2) to determine the association between 
the herd-level antimicrobial consumption and the IZD 
of non-aureus staphylococci and Staph. aureus isolates, 
respectively, and (3) to determine the association be-
tween the IZD of the non-aureus staphylococci and 
Staph. aureus isolates originating from the same herds.
MATERIALS AND METHODS
Herds and Cows
Data collected for this study originated from a conve-
nience sample of 56 Flemish dairy herds. Herd inclusion 
criteria were (1) participation in the DHI program in 
Flanders with an interval of 4 to 6 wk between 2 test-
days, and (2) record keeping of all treatments in adult 
cattle (date of occurrence, identification number of ani-
mal, treatment protocol applied). More details about 
the included herds are described elsewhere (Stevens et 
al., 2016).
From March to April 2014, approximately 10 lactat-
ing cows per herd with subclinical mastitis (defined as 
a test-day SCC >150,000 cells/mL and >250,000 cells/
mL for heifers and multiparous cows, respectively) were 
randomly selected for milk sampling for bacteriological 
culturing.
Antimicrobial Consumption Data
Antimicrobial consumption data were retrieved by 
so-called garbage can audits, as described in a previous 
paper reporting on the antimicrobial consumption of 
the herds between January 2012 and February 2013 
(Stevens et al., 2016). For the current paper, empty 
antimicrobial receptacles collected from March 2013 to 
February 2014 were used. Product name, volume, and 
number of receptacles were registered using a datasheet 
that included herd identification number and start and 
end date of collection for that particular herd. The 
quantification of the herd-level antimicrobial consump-
tion was defined by the antimicrobial treatment inci-
dence (ATI) as described previously (Stevens et al., 
2016) and expressed as the number of defined daily 
doses animal (DDDA) used per 1,000 cows per day.
Classification of Antimicrobials
Route of Administration and Indication. Anti-
microbials registered for intramammary use were divid-
ed into intramammary injectors registered for dry-cow 
therapy and injectors registered for the intramammary 
treatment of (sub)clinical mastitis cases. All systemi-
cally injectable antimicrobials used for the therapy of 
various diseases (including mastitis) are hereafter 
referred to as “systemically administered therapy.” In-
trauterine use of antimicrobials was very limited and 
therefore not taken into account in further analyses, as 
was done previously (Stevens et al., 2016).
Strata of Antimicrobials. Four strata were 
generated based on classification as β-lactam and 
non-β-lactam and their importance in human health: 
critically important (i.e., third- and fourth-generation 
cephalosporins and fluoroquinolones) or not critically 
important, according to the Office International des 
Épizooties (OIE) classification: stratum 1: critically 
important β-lactam antimicrobials (i.e., third- and 
fourth-generation cephalosporins); stratum 2: critically 
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important non-β-lactam antimicrobials (i.e., fluoroqui-
nolones); stratum 3: not critically important β-lactam 
antimicrobials (i.e., aminopenicillins, aminopenicillin-
clavulanic acid combination, aminopenicillin-poly-
myxin combination, first-generation cephalosporins, 
first-generation cephalosporin-aminoglycoside combi-
nation, penicillins, penicillin-aminopenicillin combina-
tion, and the penicillin-aminoglycoside combination); 
and stratum 4: not critically important non-β-lactam 
antimicrobials (i.e., aminoglycosides, lincosamides, 
lincosamide-aminoglycoside combination, macrolides, 
polymyxins, rifaximins, sulfonamide-trimethoprim 
combination, and tetracyclines).
Collection of Milk Samples
Quarter foremilk samples were collected aseptically 
by either the farmer or the first author and colleagues 
of the research group at milking (or between successive 
milkings on herds equipped with an automatic milking 
system) following the guidelines of the National Masti-
tis Council (Oliver et al., 2004). Sample materials were 
provided to the farmers and (aseptic) sampling proce-
dures were explained. Sampling date, cow identifica-
tion number, and quarter position were recorded. The 
quarter milk samples were transported under cooled 
conditions to the Flemish Milk Control Centre (MCC, 
Lier, Belgium), where routine bacteriological culturing 
was performed.
Bacteriological Culturing
Bacteriological culturing was performed following 
the National Mastitis Council guidelines (NMC, 1999). 
From each sample, 10 µL of milk was spread on a quad-
rant of an esculin blood agar plate (Oxoid, Basingstoke, 
UK) and incubated aerobically at 37°C for 24 to 48 h. 
Samples were considered to be culture-positive if one or 
more colonies were observed (≥100 cfu/mL). Identifica-
tion of bacteria was done by Gram staining, inspection 
of colony morphology, and biochemical testing. The 
catalase test was used to distinguish staphylococci 
(positive reaction) from the Streptococcus-Enterococcus 
group (negative reaction). Staphylococcus aureus were 
differentiated from non-aureus staphylococci by colony 
morphology, hemolysis patterns, and DNase tests. A 
DNase test was considered positive if the clearing zone 
was 3 times the width of the incubation streak and 
negative/intermediate positive when the zone was less 
than 3 times the width of the streak. An isolate was 
considered as Staph. aureus when showing a complete 
or double hemolytic pattern after 48 h of incubation 
and a positive DNase test. All other catalase-positive 
isolates (thus, isolates showing no or single hemolysis 
and a negative/intermediate DNase test) were defined 
as “non-aureus staphylococcus”). Testing of DNase ac-
tivity has a sensitivity of 97% and a specificity of 83% 
after a 24-h incubation for Staph. aureus (Graber et 
al., 2009). Samples yielding 2 different bacterial species 
were considered mixed samples and were, in case of 
staphylococci, included in the analyses. Samples yield-
ing 3 or more different bacterial species were considered 
contaminated, and Staphylococcus species from these 
samples were not further examined.
Inhibition Zone Diameters
All isolates identified as non-aureus staphylococci 
and Staph. aureus isolates were submitted to agar disk 
diffusion testing (Bauer et al., 1966) on Mueller-Hinton 
agar (i2a, Perols, France) as described previously 
(Supré et al., 2014). In short, with the InoClic system 
(i2a), used as described by the manufacturer, a clearly 
separate colony of the bacteria of interest was picked 
and suspended in 5 mL of saline solution, resulting in 
0.5 McFarland. The suspension was used for flooding 
the abovementioned agar plates (i2a) and the excess 
solution was discarded. Antibiotic-impregnated paper 
disks were applied with a dispenser.
The panel consisted of fourth-generation cephalo-
sporin (cefquinome, 30 µg), fluoroquinolone (mar-
bofloxacin, 5 µg), the amoxicillin-clavulanic acid 
combination (20/10 µg), aminopenicillin (ampicillin, 
10 µg), first-generation cephalosporin (cephalonium, 
30 µg), macrolide (erythromycin, 15 µg), lincomycin 
(15 µg), oxacillin (1 µg), aminoglycoside (neomycin, 30 
µg), rifaximin (40 µg), the sulfonamide-trimethoprim 
combination (23.75/1.25 µg), and tetracycline (30 µg). 
Disks were purchased from i2a, except for cefquinome, 
cephalonium, and rifaximin (Mast Group, Merseyside, 
UK). After an overnight incubation at 35 ± 2°C, plates 
were read with the SIRscan Micro reader (i2a). The 
reference strain Staph. aureus ATCC 25923 was used 
for quality control. Oxacillin was used for detecting 
methicillin-resistant Staph. aureus, because no structur-
al difference is observed between oxacillin and cefoxitin 
testing for this bacterium in the Flemish Milk Control 
Centre laboratory (Lier, Belgium; data not shown). No 
further investigation was performed to confirm methi-
cillin resistance.
Statistical Analyses
Before statistical analyses, all outcome and indepen-
dent variables were transformed into a normal distribu-
tion. Because the conventional ways of transformation 
(e.g., log10, ln, inverse, square root, quadratic) were not 
sufficient to obtain normally distributed variables, a 
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2-step approach as described by Templeton (2011) was 
applied. The first step involved transforming the vari-
able into a percentile rank, which resulted in uniformly 
distributed probabilities. The second step applied the 
inverse-normal transformation to the results of the first 
step to form a variable consisting of normally distrib-
uted z-scores. The mean and standard deviation of the 
original variable were retained to improve the interpre-
tation of the results.
After normalization of the data, the association 
between stratum-specific herd-level antimicrobial con-
sumption (i.e., strata 1 to 4) and the IZD (in mm) of 
individual non-aureus staphylococci and Staph. aureus 
isolates, clustered on the herd level, was evaluated by 
fitting several separate linear mixed regression models 
with the IZD of different active substances (cefquinome, 
marbofloxacin, amoxicillin-clavulanic acid, ampicil-
lin, erythromycin, cephalonium, lincomycin, oxacillin, 
neomycin, rifaximin, sulfonamide-trimethoprim, and 
tetracycline) for non-aureus staphylococci and Staph. 
aureus, respectively, as continuous outcome variables. 
Per outcome variable, a univariable model was first fit 
with the stratum-specific herd-level total ATI as con-
tinuous independent variable, and then a multivariable 
model was fit including the stratum-specific herd-level 
ATI for intramammary therapy of (sub)clinical masti-
tis, ATI for intramammary dry-cow therapy, and ATI 
for systemically administered therapy as continuous 
independent variables.
Second, the association between the IZD of indi-
vidual non-aureus staphylococci and the IZD of indi-
vidual Staph. aureus isolates originating from the same 
herds was studied by fitting univariable linear mixed 
regression models with the IZD of different active 
substances (cefquinome, marbofloxacin, amoxicillin-
clavulanic acid, ampicillin, cephalonium, erythromycin, 
lincomycin, neomycin, oxacillin, rifaximin, sulfonamide-
trimethoprim, and tetracycline) for the non-aureus 
staphylococci as continuous outcome variables, and the 
calculated average herd-level IZD of Staph. aureus for 
each antimicrobial substance as continuous indepen-
dent variable.
All models contained herd as a random effect to ad-
just for clustering of isolates within a herd and were fit 
using PROC MIXED in SAS 9.4 (SAS Institute Inc., 
Cary, NC). The goodness-of-fit measures included −2 
× log-likelihood, Akaike information criterion, and 
Bayesian information criterion, using PROC MIXED 
in SAS 9.4 (SAS Institute Inc.). The conditional Pear-
son residuals were evaluated graphically and graphed 
against the normal values and predicted values to check 
whether the assumptions of normality and homogeneity 
had been fulfilled, respectively. Also, plots of standard-
ized residuals versus the dependent variables were gen-
erated to check whether the assumption of linearity had 
been fulfilled. No problems were detected. Significance 
was assessed at P ≤ 0.05. As multiple associations were 
investigated, the false discovery rate was calculated us-
ing SPSS 24.0 (SPSS Inc./IBM Corp., Chicago, IL).
RESULTS
Total Antimicrobial Consumption
The average total ATI was 18.73 DDDA per 1,000 
cow-days (Table 1), with a large variation between 
herds, ranging from 6.28 to 42.13 DDDA. β-Lactam 
antimicrobials, both critically important and not criti-
cally important, were used in large amounts in the dairy 
herds. Third- and fourth-generation cephalosporins and 
penicillins were used on 47, 50, and 51 herds out of 
the 56 herds, respectively (Table 1). Fourth-generation 
cephalosporins had the highest ATI (3.57 DDDA per 
1,000 cow-days) followed by penicillins (3.23 DDDA) 
and third-generation cephalosporins (2.95 DDDA).
Classification of Antimicrobials
Route of Administration and Indication. Anti-
microbials administered intramammary had the high-
est ATI (11.90 DDDA per 1,000 cow-days) followed by 
systemically administered antimicrobials (6.73 DDDA; 
Table 1). The use of antimicrobials administered by 
other routes (e.g., intrauterine) was very low (0.10 
DDDA) and therefore not included in this analysis, 
as mentioned previously. The ATI for intramammary 
dry-cow therapy was 6.70 DDDA and that for intra-
mammary therapy of (sub)clinical mastitis cases 5.20 
DDDA. Dry-cow injectors containing fourth-generation 
cephalosporins had the highest ATI (1.92 DDDA), fol-
lowed by first-generation cephalosporins and penicillins 
(1.68 and 1.30 DDDA, respectively). For the intramam-
mary treatment of (sub)clinical mastitis, the combina-
tion first-generation cephalosporins-aminoglycosides 
had the highest ATI (1.63 DDDA). A large majority 
of the herds used fourth-generation cephalosporins and 
the combination of first-generation cephalosporins with 
aminoglycosides (n = 39 and n = 36, respectively) for 
the treatment of (sub)clinical mastitis.
The average ATI for systemically administered 
therapy was 6.73 DDDA of which third-generation 
cephalosporins had the highest ATI (2.66 DDDA), fol-
lowed by penicillins (1.92 DDDA) and macrolides (0.93 
DDDA). Penicillins, third-generation cephalosporins, 
and macrolides were used systemically on 47, 46, and 
40 herds, respectively.
Strata of Antimicrobials. The average ATI of 
critically important antimicrobials was 6.91 DDDA 
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(range 0.00–26.34 DDDA) whereas that for not criti-
cally important antimicrobials was 11.83 DDDA (range 
0.00–24.76 DDDA; Table 1).
Critically important β-lactams were used on the ma-
jority of the herds, with an average ATI of 6.52 DDDA 
(range 0.00–26.34 DDDA). Critically important non-β-
lactam antimicrobials, in contrast, were only used on 
29 herds, with a low average ATI (0.39 DDDA; range 
0.00–2.54 DDDA). A similar distribution was observed 
for the not critically important antimicrobials, where 
the average ATI of β-lactam antimicrobials was higher 
than that of non-β-lactam antimicrobials (10.12 and 
1.71 DDDA, with a range of 0.52–24.76 and 0.00–6.43 
DDDA, respectively).
Distribution of IZD
A total of 239 non-aureus staphylococci and 88 
Staph. aureus isolates originating from 47 and 33 herds, 
respectively, were submitted to agar disk diffusion test-
ing. The number of tested isolates per herd varied from 
1 to 13 and from 1 to 14 for non-aureus staphylococci 
and Staph. aureus, respectively. The distribution of IZD 
of non-aureus staphylococci and Staph. aureus is pre-
sented in Table 2. The median IZD of the non-aureus 
staphylococci and Staph. aureus isolates were 33.0 and 
34.0 for cefquinome, 30.0 and 29.0 for marbofloxacin, 
39.0 and 40.0 for amoxicillin-clavulanic acid, 34.0 and 
40.0 for ampicillin, 35.0 and 40.0 for cephalonium, 28.0 
and 27.5 for erythromycin, 30.0 and 31.0 for linco-
mycin, 24.0 and 21.0 for neomycin, 23.0 and 27.0 for 
oxacillin, 35.0 and 31.0 for rifaximin, 27.0 and 29.0 for 
sulfonamide-trimethoprim, and 32.0 and 31.0 mm for 
tetracyclines, respectively.
For some isolates, growth was barely inhibited by the 
presence of the antimicrobial disk (IZD of 6 mm) in the 
agar disk diffusion testing, specifically 10 and 1 isolate(s) 
for the non-aureus staphylococci-erythromycin and 
Staph. aureus-erythromycin combination, respectively; 
18 and 3 isolates for the non-aureus staphylococci-
lincomycin and Staph. aureus-lincomycin combination, 
respectively; 3 and 2 for the non-aureus staphylococci-
marbofloxacin and Staph. aureus-marbofloxacin combi-
nation, respectively; 5 and 2 isolates for the non-aureus 
staphylococci-sulfonamide-trimethoprim and Staph. 
aureus-sulfonamide-trimethoprim, respectively; 4 iso-
lates for the Staph. aureus-oxacillin combination and 2 
isolates for the non-aureus staphylococci–tetracyclines 
combination (Table 2).
Associations Between ATI and IZD. Associa-
tions between herd-level ATI (i.e., ATI overall, ATI for 
intramammary therapy of (sub)clinical mastitis, ATI 
for intramammary dry-cow therapy, and ATI for sys-
temically administered therapy, respectively) and the 
IZD of non-aureus staphylococci and Staph. aureus 
obtained by Kirby-Bauer disk diffusion are presented 
in Figure 1.
For non-aureus staphylococci, the ATI for systemic 
therapy of critically important β-lactam antimicrobials 
was negatively associated with the IZD for cefquinome, 
whereas the ATI for intramammary therapy of (sub)
clinical mastitis of critically important β-lactam anti-
microbials was positively associated with the IZD for 
cefquinome (P = 0.04 and P = 0.05, false discovery rate 
= 84 and 51%, respectively).
Association Between IZD of Non-Aureus 
Staphylococcus and Staph. aureus. Only for neo-
mycin was a positive association between the IZD of 
non-aureus staphylococci and Staph. aureus isolates 
within the same herd observed (P < 0.01; false discov-
ery rate: 0.12%).
DISCUSSION
Besides precisely quantifying antimicrobial consump-
tion on several commercial dairy herds, we investigated 
the association between herd-level antimicrobial con-
sumption and IZD, used as a proxy for the presence 
of antimicrobial resistance, focusing on non-aureus 
staphylococci (frequently found in milk samples from 
dairy cows) and Staph. aureus (an important major 
mastitis pathogen).
The average total ATI in this study was 18.73 DDDA 
per 1,000 cow-days, which is high compared with the 
14.35, 3.56, 16.05, 14.28, and 4.66 DDDA per 1,000 
cow-days obtained in studies in Canada (Saini et al., 
2012a), Austria (Obritzhauser et al., 2016), the Neth-
erlands (Kuipers et al., 2016), Argentina (González 
Pereyra et al., 2015), and New Zealand (McDougall 
et al., 2016), respectively. Similar to the data obtained 
in Austria, critically important (for human health) 
antimicrobials accounted for a large part of the total 
antimicrobial consumption (Obritzhauser et al., 2016). 
However, differences in the calculation of antimicrobial 
consumption hamper a straightforward comparison of 
the results between the studies (Collineau et al., 2017). 
The total ATI on the same herds during 2012 and 
2013 was 20.78 DDDA per 1,000 cow-days (Stevens et 
al., 2016), which is slightly higher than described in 
this article. Because the current study included data 
obtained as part of a larger 2-yr project, half of the 
herds included received mastitis management input 
on a 4- to 6-weekly basis (intervention group) and 28 
herds did not receive mastitis management input but 
were requested to collect and record the data (control 
group). In accordance with Kuipers et al. (2016), the 
expected effect of mastitis management input on a 
dairy herd’s antimicrobial consumption over 2 yr is 
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limited. The latter assumption appears to be reinforced 
by the preliminary results obtained in our work in prog-
ress. In fact, antimicrobial consumption and changes 
in antimicrobial consumption on dairy herds seem to 
be more influenced by changes in mastitis manage-
ment over time independently of the group to which 
they were assigned rather than by whether the farm 
received mastitis management input from the first au-
thor. Given that, we concluded that the effect of the 
farm-based intervention on the results described in 
this study and their extrapolation is expected to be 
very limited or nonexistent. Still, we hypothesize that 
the establishment of a national center of expertise on 
antimicrobial consumption and resistance in animals 
(AMCRA, 2014) in 2012 because of political interest 
in emerging antimicrobial resistance might have played 
a role as it evolved into several nationwide awareness 
campaigns targeting farmers and veterinarians, among 
other projects that were initiated during the time our 
study was executed.
The Kirby-Bauer disk diffusion method, performed 
at the Flemish MCC (Lier, Belgium) as part of routine 
analyses, has a moderate to high diagnostic accuracy 
and categorical agreement for most udder pathogen-
antimicrobial combinations (Saini et al., 2011), particu-
larly if plates are read by using the SIRscan Micro (i2a) 
as was done in this study. Because only a limited num-
ber of clinical breakpoints (CLSI) and epidemiological 
cut off values (EUCAST) are available for mastitis-
causing bacteria, we refrained from using cut-off values 
to stratify isolates into susceptible and resistant popu-
lations. Rather, we opted to report IZD and use them 
as a proxy for antimicrobial resistance when looking 
for associations with antimicrobial consumption. Still, 
for most Staph. aureus and non-aureus staphylococci-
antimicrobial active substance combinations, a bimodal 
distribution was observed, indicating the presence of 
acquired resistance in some isolates. Corresponding to 
the work of Supré et al. (2014), separation of 2 popula-
tions based on the curve was less obvious for the Staph. 
Figure 1. Visualization of associations between inhibition zone diameters (IZD, mm) (CEFQ, cefquinome; MAR, marbofloxacin; AMC, 
amoxicillin-clavulanic acid; AMP, ampicillin; CEPH, cephalonium; OXA, oxacillin) of (A) non-aureus staphylococci, and (B) Staphylococcus 
aureus from cows with subclinical mastitis and the herd-level antimicrobial consumption expressed as the antimicrobial treatment incidence 
(ATI) in defined daily dose animal (DDDA) per 1,000 cow-days for 3 strata of antimicrobials: (top) critically important β-lactams (third- and 
fourth-generation cephalosporins), (middle) critically important non-β-lactams (fluoroquinolones), (bottom) not critically important β-lactams 
(aminopenicillins, aminopenicillin-clavulanic acid, aminopenicillin-polymyxin, first-generation cephalosporins, first-generation cephalosporin-
aminoglycoside, penicillins, penicillin-aminopenicillin, penicillin-aminoglycoside). The horizontal bars represent the β (regression factor) origi-
nating from univariable models for ATI overall and from multivariable models for herd-level ATI for intramammary therapy of (sub)clinical 
mastitis, ATI for intramammary dry-cow therapy, and ATI for systemically administered therapy, respectively (see Materials and Methods). 
*For non-aureus staphylococci, the ATI for systemic therapy of critically important β-lactam antimicrobials was negatively associated with the 
IZD for cefquinome (P = 0.04 with a false-discovery rate of 84%) and the ATI for intramammary therapy of (sub)clinical mastitis of critically 
important β-lactam antimicrobials was positively associated with the IZD for cefquinome (P = 0.05 with false discovery rate of 51%). (1) The β 
of “ATI overall” is equal to the β of “ATI for systemically administered therapy.” In Belgium, Marbofloxacine is only available for systemic use.
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aureus-ampicillin combination. This indistinctness was 
also observed for the non-aureus staphylococci-oxacillin 
combination.
The negative association between ATI for systemic 
therapy of critically important β-lactam antimicrobials 
and IZD of non-aureus staphylococci for cefquinome 
might be explained by the (partial) commensal char-
acter of non-aureus staphylococci. Because of that 
commensal character, non-aureus staphylococci are 
more likely to be exposed to whatever (systemically 
administered) antimicrobial therapy. The negative as-
sociation between ATI for systemic therapy of critically 
important β-lactam antimicrobials and IZD of non-
aureus staphylococci for cefquinome (representing the 
critically important β-lactams) is, in this respect, not 
that surprising and, in fact, confirms selection pressure, 
because the critically important β-lactam antimicrobi-
als represent about one-third of the total antimicro-
bial consumption (6.52 DDDA, of which almost 50% 
was used as systemically administered therapy). Still, 
caution is needed in the interpretation of the data. 
Although statistically significant associations between 
IZD and ATI were found in the present study, this does 
not prove causality. When studying larger data sets 
with many variables and associations as in the present 
study, the probability of finding associations by chance 
increases substantially (Dohoo et al., 1997). Given that, 
in theory, for every 20 comparisons, a significant differ-
ence will be found purely by coincidence without having 
a real difference (Dewulf et al., 2009), the associations 
between ATI for systemic therapy of critically impor-
tant β-lactam antimicrobials and IZD of cefquinome 
and the herd-level ATI for intramammary therapy of 
(sub)clinical mastitis of critically important β-lactam 
antimicrobials on the one hand and the IZD of non-
aureus staphylococci for cefquinome on the other hand 
might be due to chance, as reflected by the high false 
discovery rates. In addition, factors that potentially 
influence both IZD and herd-level ATI could act as 
confounders. Still, including herd as a random effect, 
as done in this study, takes into account the associa-
tion between isolates within the same herd, and thus 
controls for any confounding factor at the herd level 
(Dohoo et al., 2003).
The most common resistance mechanism in staphylo-
cocci is the production of β-lactamase, which results in 
resistance to penicillin G and aminopenicillins (Persson 
Waller et al., 2011; Preethirani et al., 2015; Schmidt 
et al., 2015). In our results, the trend to resistance, as 
reflected by a smaller IZD for penicillin G and amino-
penicillins, was not pronounced, which is in accordance 
with findings of Sawant et al. (2009). Still, we are cau-
tious in drawing conclusions about antimicrobial resis-
tance in our study, because IZD were used as a proxy 
for antimicrobial resistance only, and small IZD in the 
absence of cut-offs and clinical breakpoints are only an 
indication for the presence of antimicrobial resistance. 
Moreover, comparison between different studies is likely 
not legitimate, because different sampling strategies, 
different susceptibility testing methods (Kirby-Bauer 
disk diffusion versus broth dilution method), and dif-
ferent interpretive criteria have been used to categorize 
isolates as either susceptible or resistant. Also, because 
we did not identify non-aureus staphylococci to the 
species level and susceptibility to antimicrobials varies 
between staphylococcal species (Sawant et al., 2009; 
Bal et al., 2010; Persson Waller et al., 2011; Schmidt et 
al., 2015; Raspanti et al., 2016), part of the large varia-
tion might be explained by differences in IZD between 
non-aureus staphylococci species.
The positive association in IZD between non-aureus 
staphylococci and Staph. aureus for neomycin could be 
explained by the fact that many of the genes encoding 
neomycin resistance reside on mobile genetic elements, 
which can be exchanged between bacteria of the same 
or different species occupying the same ecological niche 
(Lyon and Skurray, 1987; Lindsay and Holden, 2006).
CONCLUSIONS
The average ATI on a convenience sample of Flemish 
dairy herds was high, with a large between-herd varia-
tion. Most antimicrobials were used for intramammary 
therapy. Fourth-generation cephalosporins, critically 
important for human health, had the highest ATI. A 
decrease in the antimicrobial susceptibility of non-au-
reus staphylococci with increasing systemic administra-
tion of critically important β-lactam antimicrobials was 
suggested. In contrast, the use of critically important 
β-lactam antimicrobials for intramammary treatment 
of (sub)clinical mastitis did not seem to affect the an-
timicrobial susceptibility of non-aureus staphylococci. 
The IZD of non-aureus staphylococci and Staph. aureus 
were positively associated for neomycin.
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